X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (73) 73
humans (65) 65
urology & nephrology (46) 46
female (44) 44
male (44) 44
middle aged (43) 43
aged (35) 35
albuminuria (33) 33
risk factors (32) 32
type 2 diabetes (26) 26
glomerular filtration rate (24) 24
diabetes (23) 23
mortality (23) 23
adult (22) 22
blood-pressure (22) 22
chronic kidney disease (21) 21
endocrinology & metabolism (21) 21
chronic kidney-disease (19) 19
nephropathy (19) 19
glomerular-filtration-rate (18) 18
diabetes mellitus (17) 17
risk (17) 17
diabetes mellitus, type 2 - complications (16) 16
progression (16) 16
disease progression (15) 15
hypertension (15) 15
kidney diseases (15) 15
analysis (14) 14
sodium (14) 14
blood pressure (13) 13
creatinine (13) 13
disease (13) 13
microalbuminuria (13) 13
nephrology (13) 13
biomarkers - blood (12) 12
cardiovascular diseases (12) 12
diabetic nephropathies - drug therapy (12) 12
diabetic nephropathy (12) 12
double-blind (12) 12
research (12) 12
chronic kidney failure (11) 11
clinical trials (11) 11
medical research (11) 11
proteinuria (11) 11
care and treatment (10) 10
diabetes mellitus, type 2 - blood (10) 10
diabetes mellitus, type 2 - drug therapy (10) 10
double-blind method (10) 10
drug therapy (10) 10
treatment outcome (10) 10
abridged index medicus (9) 9
diabetes mellitus, type 2 - physiopathology (9) 9
diabetic nephropathies (9) 9
medicine, experimental (9) 9
peripheral vascular disease (9) 9
population (9) 9
post-hoc analysis (9) 9
stage renal-disease (9) 9
angiotensin (8) 8
biomarkers (8) 8
dapagliflozin (8) 8
development and progression (8) 8
diabetic nephropathies - physiopathology (8) 8
diabetic-nephropathy (8) 8
kidney-disease (8) 8
kidneys (8) 8
patients (8) 8
prognosis (8) 8
prospective studies (8) 8
renal insufficiency, chronic - physiopathology (8) 8
transplantation (8) 8
albumin (7) 7
albuminuria - etiology (7) 7
albuminuria - physiopathology (7) 7
angiotensin receptor antagonists - therapeutic use (7) 7
association (7) 7
biomarkers - urine (7) 7
cardiovascular disease (7) 7
cardiovascular events (7) 7
complications and side effects (7) 7
cross-over studies (7) 7
empagliflozin (7) 7
hypoglycemic agents - therapeutic use (7) 7
irbesartan (7) 7
kidney (7) 7
kidney - physiopathology (7) 7
losartan (7) 7
renin-angiotensin system - drug effects (7) 7
urologic and male genital diseases (7) 7
albuminuria - prevention & control (6) 6
albuminuria - urine (6) 6
angiotensin-converting enzyme inhibitors - therapeutic use (6) 6
blood pressure - drug effects (6) 6
cardiac & cardiovascular systems (6) 6
ckd (6) 6
cohort studies (6) 6
collaborative metaanalysis (6) 6
diabetes mellitus, type 2 - metabolism (6) 6
diabetic kidney disease (6) 6
epidermal growth factor receptors (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 06/2019, Volume 7, Issue 6, pp. 415 - 417
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 06/2019
To explore the added value of diabetes-related genetic risk scores to readily available clinical parameters in the prediction of HbA1c levels after initiation... 
Journal Article
Current Opinion in Nephrology and Hypertension, ISSN 1062-4821, 08/2019
PURPOSE OF REVIEWChronic kidney disease is a global health problem with few effective therapies available that slow the progression to end-stage renal disease.... 
Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2019, Volume 21, Issue 10, pp. 2267 - 2273
Aim To explore the added value of diabetes‐related genetic risk scores (GRSs) to readily available clinical variables in the prediction of glycated haemoglobin... 
diabetes risk genes | antidiabetic agents | type 2 diabetes mellitus | metformin | sulphonylurea derivatives | glucose‐lowering therapy | HbA1c | glucose-lowering therapy | Prediction models | Diabetes mellitus | Hemoglobin | Single-nucleotide polymorphism | Diabetes | Metformin | Diabetes mellitus (non-insulin dependent) | Patients | Insulin | Index Medicus
Journal Article
Current Opinion in Nephrology and Hypertension, ISSN 1062-4821, 07/2019, Volume 28, Issue 4, pp. 321 - 327
Journal Article
Diabetes Care, ISSN 0149-5992, 08/2019, p. dc190937
OBJECTIVEIn people with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risk and progression of diabetic kidney... 
Index Medicus
Journal Article
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 05/2017, Volume 12, Issue 5, pp. 751 - 759
Background and objective Sodium glucose cotransporter 2 inhibition with dapagliflozin decreases hemoglobin A1c (HbAlc), body weight, BP, and albuminuria... 
Cardiovascular Diseases | Body Weight | Benzhydryl Compounds | Cardiovascular | Humans | Hematocrit | Albuminuria | Risk factors | Glomerular filtration rate | Hypoglycemic Agents | Diabetic nephropathy | Blood pressure | Diabetes Mellitus, Type 2 | Natriuresis | Glucosides | REDUCES ALBUMINURIA | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | CONTROLLED 102-WEEK TRIAL | COTRANSPORTER 2 INHIBITION | CHRONIC KIDNEY-DISEASE | TYPE-2 DIABETES-MELLITUS | POST-HOC ANALYSIS | INADEQUATE GLYCEMIC CONTROL | BLOOD-PRESSURE | Albuminuria - epidemiology | Biomarkers - urine | Cardiovascular Diseases - prevention & control | Glycated Hemoglobin A - metabolism | Middle Aged | Male | Diabetes Mellitus, Type 2 - epidemiology | Protective Factors | Albuminuria - physiopathology | Clinical Trials, Phase III as Topic | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Female | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Kidney Tubules, Proximal - pathology | Glomerular Filtration Rate | Risk Assessment | Sodium-Glucose Transporter 2 - metabolism | Risk Factors | Hemoglobins - metabolism | Treatment Outcome | Biomarkers - blood | Albuminuria - prevention & control | Creatinine - urine | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Kidney Tubules, Proximal - metabolism | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Kidney Tubules, Proximal - drug effects | Index Medicus | blood pressure | risk factors | glomerular filtration rate | cardiovascular | albuminuria | Original | diabetic nephropathy
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 2017, Volume 32, Issue 9, pp. 1510 - 1516
Background. Chronic kidney disease (CKD) progression is currently assessed by a decline in estimated glomerular filtration rate (eGFR) and/or an increase in... 
Urine | chronic kidney disease | Albuminuria | Peptides | CKD273 | Proteome analysis | FIBROSIS | DIAGNOSIS | POPULATION | urine | VALIDATION | peptides | DIABETIC-NEPHROPATHY | proteome analysis | MASS-SPECTROMETRY | TRANSPLANTATION | albuminuria | BIOMARKER DISCOVERY | UROLOGY & NEPHROLOGY | CHRONIC KIDNEY-DISEASE | PROGRESSION | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 1988 - 1993
The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects... 
acute kidney injury | type 2 diabetes | MCP‐1 | SGLT‐2 | dapagliflozin | KIM‐1 | KIM-1 | MCP-1 | SGLT-2 | DIABETIC-NEPHROPATHY | HYPOXIA | DAMAGE | DECLINE | INFLAMMATION | DISEASE | ENDOCRINOLOGY & METABOLISM | KIDNEY | EMPAGLIFLOZIN | Inflammation Mediators - urine | Kidney Tubules - physiopathology | Biomarkers - urine | Humans | Kidney Glomerulus - physiopathology | Diabetes Mellitus, Type 2 - metabolism | Diabetic Nephropathies - immunology | Interleukin-6 - urine | Glomerular Filtration Rate - drug effects | Netherlands | Benzhydryl Compounds - adverse effects | Acute Kidney Injury - complications | Adult | Glucosides - therapeutic use | Acute Kidney Injury - immunology | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Kidney Tubules - immunology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Albuminuria - etiology | Double-Blind Method | Kidney Tubules - drug effects | Kidney Glomerulus - drug effects | Inflammation Mediators - blood | Renal Elimination - drug effects | Biomarkers - blood | Albuminuria - prevention & control | Acute Kidney Injury - prevention & control | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Diabetes Mellitus, Type 2 - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Hepatitis A Virus Cellular Receptor 1 - metabolism | Kidney Glomerulus - immunology | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Albumin | Analysis | Immunoglobulin G | Excretion | Inflammation | Cell injury | Diabetes | Epidermal growth factor receptors | Index Medicus | Brief Reports | Brief Report
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 10/2017, Volume 12, Issue 10, pp. 1595 - 1600
Background and objectives: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both... 
Creatinine | Nephrology | Diabetes mellitus, type 2 | Humans | Diabetic nephropathies | Tetrazoles | Linear models | Kidney | Glomerular filtration rate | Irbesartan | Losartan | Renal dialysis | Renal replacement therapy | Angiotensin II | Biphenyl compounds | SERUM CREATININE | CHOICE | DECISION | GFR | UROLOGY & NEPHROLOGY | START | IRBESARTAN | NEPHROPATHY | PROGRESSION | DECLINE | Up-Regulation | Angiotensin II Type 1 Receptor Blockers - adverse effects | Renal Insufficiency, Chronic - etiology | Diabetic Nephropathies - etiology | Health Status Indicators | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Biphenyl Compounds - adverse effects | Diabetic Nephropathies - drug therapy | Biphenyl Compounds - therapeutic use | Glomerular Filtration Rate - drug effects | Diabetic Nephropathies - physiopathology | Time Factors | Clinical Decision-Making | Endpoint Determination | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Kidney - drug effects | Risk Factors | Proportional Hazards Models | Linear Models | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Renal Insufficiency, Chronic - prevention & control | Diabetes Mellitus, Type 2 - physiopathology | Losartan - therapeutic use | Creatinine - blood | Losartan - adverse effects | Tetrazoles - therapeutic use | Clinical Trials as Topic - methods | Tetrazoles - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Health Status | Research Design | Renal Dialysis | Index Medicus | irbesartan | Diabetic Nephropathies | glomerular filtration rate | Renal Replacement Therapy | Biphenyl Compounds | nephrology | kidney | creatinine | Diabetes Mellitus, Type 2 | Original | renal dialysis
Journal Article